<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://www.herpesviridae.org/feeds/latestarticles/journal?quantity=&amp;format=rss&amp;version=">
        <title>Herpesviridae - Latest Articles</title>
        <link>http://www.herpesviridae.org</link>
        <description>The latest research articles published by Herpesviridae</description>
        <dc:date>2013-01-23T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.herpesviridae.org/content/4/1/1" />
                                <rdf:li rdf:resource="http://www.herpesviridae.org/content/3/1/6" />
                                <rdf:li rdf:resource="http://www.herpesviridae.org/content/3/1/5" />
                                <rdf:li rdf:resource="http://www.herpesviridae.org/content/3/1/4" />
                                <rdf:li rdf:resource="http://www.herpesviridae.org/content/3/1/3" />
                                <rdf:li rdf:resource="http://www.herpesviridae.org/content/3/1/2" />
                                <rdf:li rdf:resource="http://www.herpesviridae.org/content/3/1/1" />
                                <rdf:li rdf:resource="http://www.herpesviridae.org/content/2/1/10" />
                                <rdf:li rdf:resource="http://www.herpesviridae.org/content/2/1/9" />
                                <rdf:li rdf:resource="http://www.herpesviridae.org/content/2/1/8" />
                            </rdf:Seq>
        </items>
                 <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.herpesviridae.org/content/4/1/1">
        <title>Cytomegalovirus-induced salivary gland pathology: resistance to kinase inhibitors of the upregulated host cell EGFR/ERK pathway is associated with CMV-dependent stromal overexpression of IL-6 and fibronectin</title>
        <description>Background:
Recently we identified a relationship between human cytomegalovirus (hCMV) and human salivary gland (SG) mucoepidermoid carcinoma (MEC) in over 90% of cases; tumorigenesis in these cases uniformly correlated with active hCMV protein expression and an upregulation of the EGFR &#8594; ERK pathway. Our previously characterized, novel mouse organ culture model of mouse CMV (mCMV)-induced tumorigenesis displays a number of histologic and molecular characteristics similar to human MEC.
Methods:
Newborn mouse submandibular glands (SMGs) were incubated with 1 &#215; 105 PFU/ml of lacZ-tagged mCMV RM427+ on day 0 for 24 hours and then cultured in virus-free media for a total of 6 or 12 days with or without EGFR/ERK inhibitors and/or aciclovir. SMGs were collected for histology, immunolocalization (pERK, FN, IL-6), viral distribution, or Western blot analysis (pERK).
Results:
Here we report: (1) mouse SMG tumors soon exhibit an acquired resistance to EGFR/ERK pathway kinase inhibitors, alone or in combination; (2) long term tumor regression can only be sustained by concurrent inhibitor and antiviral treatment; (3) CMV-dependent, kinase inhibitor resistance is associated with overexpression of fibronectin and IL-6 proteins in abnormal stromal cells.
Conclusions:
Acquired resistance to kinase inhibitors is dependent upon CMV dysregulation of alternative pathways with downstream effectors common with the targeted pathway, a phenomenon with important therapeutic implications for human MEC of salivary glands.</description>
        <link>http://www.herpesviridae.org/content/4/1/1</link>
                <dc:creator>Michael Melnick</dc:creator>
                <dc:creator>Parish Sedghizadeh</dc:creator>
                <dc:creator>Krysta Deluca</dc:creator>
                <dc:creator>Tina Jaskoll</dc:creator>
                <dc:source>Herpesviridae 2013, null:1</dc:source>
        <dc:date>2013-01-23T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/2042-4280-4-1</dc:identifier>
                                <prism:require>/content/figures/2042-4280-4-1-toc.gif</prism:require>
                <prism:publicationName>Herpesviridae</prism:publicationName>
        <prism:issn>2042-4280</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>1</prism:startingPage>
        <prism:publicationDate>2013-01-23T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.herpesviridae.org/content/3/1/6">
        <title>HSV-1-induced chemokine expression via IFI16-dependent and IFI16-independent pathways in human monocyte-derived macrophages</title>
        <description>Background:
Innate recognition is essential in the antiviral response against infection by herpes simplex virus (HSV). Chemokines are important for control of HSV via recruitment of natural killer cells, T lymphocytes, and antigen-presenting cells. We previously found that early HSV-1-mediated chemokine responses are not dependent on TLR2 and TLR9 in human macrophages. Here, we investigated the role of the recently identified innate IFN-inducible DNA receptor IFI16 during HSV-1 infection in human macrophages.
Methods:
Peripheral blood mononuclear cells were purified from buffy coats and monocytes were differentiated to macrophages. Macrophages infected with HSV-1 were analyzed using siRNA-mediated knock-down of IFI16 by real-time PCR, ELISA, and Western blotting.
Results:
We determined that both CXCL10 and CCL3 are induced independent of HSV-1 replication. IFI16 mediates CCL3 mRNA accumulation during early HSV-1 infection. In contrast, CXCL10 was induced independently of IFI16.
Conclusions:
Our data provide the first evidence of HSV-1-induced innate immune responses via IFI16 in human primary macrophages. In addition, the data suggest that at least one additional unidentified receptor or innate sensing mechanism is involved in recognizing HSV-1 prior to viral replication.</description>
        <link>http://www.herpesviridae.org/content/3/1/6</link>
                <dc:creator>Stine Søby</dc:creator>
                <dc:creator>Rune Laursen</dc:creator>
                <dc:creator>Lars Østergaard</dc:creator>
                <dc:creator>Jesper Melchjorsen</dc:creator>
                <dc:source>Herpesviridae 2012, null:6</dc:source>
        <dc:date>2012-10-14T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/2042-4280-3-6</dc:identifier>
                                <prism:require>/content/figures/2042-4280-3-6-toc.gif</prism:require>
                <prism:publicationName>Herpesviridae</prism:publicationName>
        <prism:issn>2042-4280</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>6</prism:startingPage>
        <prism:publicationDate>2012-10-14T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.herpesviridae.org/content/3/1/5">
        <title>Herpes simplex virus and varicella zoster virus, the house guests who never leave</title>
        <description>Human alphaherpesviruses including herpes simplex viruses (HSV-1, HSV-2) and varicella zoster virus (VZV) establish persistent latent infection in sensory neurons for the life of the host. All three viruses have the potential to reactivate causing recurrent disease. Regardless of the homology between the different virus strains, the three viruses are characterized by varying pathologies. This review will highlight the differences in infection pattern, immune response, and pathogenesis associated with HSV-1 and VZV.</description>
        <link>http://www.herpesviridae.org/content/3/1/5</link>
                <dc:creator>Paul Kinchington</dc:creator>
                <dc:creator>Anthony St.Leger</dc:creator>
                <dc:creator>Jean-Marc Guedon</dc:creator>
                <dc:creator>Robert Hendricks</dc:creator>
                <dc:source>Herpesviridae 2012, null:5</dc:source>
        <dc:date>2012-06-12T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/2042-4280-3-5</dc:identifier>
                                <prism:require>/content/figures/2042-4280-3-5-toc.gif</prism:require>
                <prism:publicationName>Herpesviridae</prism:publicationName>
        <prism:issn>2042-4280</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>5</prism:startingPage>
        <prism:publicationDate>2012-06-12T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.herpesviridae.org/content/3/1/4">
        <title>The effect of mouse strain on herpes simplex virus type 1 (HSV-1) infection of the central nervous system (CNS)</title>
        <description>Background:
Mice infected with HSV-1 can develop lethal encephalitis or virus induced CNS demyelination. Multiple factors affect outcome including route of infection, virus and mouse strain. When infected with a sub-lethal dose of HSV-1 strain 2 via the oral mucosa, susceptible SJL/J, A/J, and PL/J mice develop demyelinating lesions throughout the brain. In contrast, lesions are restricted to the brainstem (BST) in moderately resistant BALB/c mice and are absent in resistant BL/6 mice. The reasons for the strain differences are unknown.
Methods:
In this study, we combine histology, immunohistochemistry, and in-situ hybridization to investigate the relationship between virus and the development of lesions during the early stage (&lt; 24 days PI) of demyelination in different strains of mice.
Results:
Initially, viral DNA and antigen positive cells appear sequentially in non-contiguous areas throughout the brains of BALB/c, SJL/J, A/J, and PL/J mice but are restricted to an area of the BST of BL/6 mice. In SJL/J, A/J, and PL/J mice, this is followed by the development of &apos;focal&apos; areas of virus infected neuronal and non-neuronal cells throughout the brain. The &apos;focal&apos; areas follow a hierarchical order and co-localize with developing demyelinating lesions. When antigen is cleared, viral DNA positive cells can remain in areas of demyelination; consistent with a latent infection. In contrast, &apos;focal&apos; areas are restricted to the BST of BALB/c mice and do not occur in BL/6 mice.
Conclusions:
The results of this study indicate that susceptible mouse strains, infected with HSV-1 via the oral mucosa, develop CNS demyelination during the first 24 days PI in several stages. These include: the initial spread of virus and infection of cells in non-contiguous areas throughout the brain, the development of &apos;focal&apos; areas of virus infected neuronal and non-neuronal cells, the co-localization of &apos;focal&apos; areas with developing demyelinating lesions, and latent infection in a number of the lesions. In contrast, the limited demyelination that develops in BALB/c and the lack of demyelination in BL/6 mice correlates with the limited or lack of &apos;focal&apos; areas of virus infected neuronal and non-neuronal cells in these two strains.</description>
        <link>http://www.herpesviridae.org/content/3/1/4</link>
                <dc:creator>Lorne Kastrukoff</dc:creator>
                <dc:creator>Allen Lau</dc:creator>
                <dc:creator>Eva Thomas</dc:creator>
                <dc:source>Herpesviridae 2012, null:4</dc:source>
        <dc:date>2012-03-26T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/2042-4280-3-4</dc:identifier>
                                <prism:require>/content/figures/2042-4280-3-4-toc.gif</prism:require>
                <prism:publicationName>Herpesviridae</prism:publicationName>
        <prism:issn>2042-4280</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>4</prism:startingPage>
        <prism:publicationDate>2012-03-26T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.herpesviridae.org/content/3/1/3">
        <title>Low levels of Human Cytomegalovirus Infection in Glioblastoma Multiforme associates with patient survival; -a case-control study</title>
        <description>Background:
Glioblastoma multiforme (GBM) represent the most aggressive brain tumor with a median overall survival of about 12-15 months. Over 90% of GBM tumors have recently been shown to be infected with human cytomegalovirus (HCMV). In this case-control study, we evaluated whether there was an association between the grade of HCMV infection and long-term survival (&gt; 18 months) in GBM patients.Material and methodsBrain tumor tissue sections from consecutive GBMs patients who survived more than 18 months (n = 40), and an equal number of GBM patients, matched to date of diagnosis and surgery, operated at Karolinska University Hospital in 2000-2005 were selected. HCMV infection grade was determined by estimation of the number of HCMV positive cells (scored negative or grade 1-4) in tumor tissue specimens. Using Chi-Square test and logistic regression analysis, we analyzed whether there was an association between long-term survival and HCMV low-grade infection or other clinical parameters known to be associated with prolonged survival of GBM patients; age under 50 years, radical surgery or low recursive partition analysis (RPA) subclass.
Results:
HCMV infection was detected in tumor samples from 79 of 80 patients (99%). Among patients surviving &gt; 18 months, HCMV infection grade 1 in the GBM tumor was predominant. A low grade HCMV infection was found in 19 patients, of these 16 survived &gt; 18 months. Thus, 16 of 40 (40%) GBM patients who lived &gt; 18 months had low-grade HCMV infection while only 3 of 40 (8%) GBM patients who lived &lt; 18 months did (p .0006, Chi-Square test). Multiple logistic regression analyses yielded an odds ratio estimate of 6.604 with 95% confidence interval (1.36-32.1) (p .019) for low grade HCMV after adjustment for RPA class III and IV, radical surgery, age and gamma knife treatment.
Conclusion:
In conclusion, we found that low-grade HCMV infection was strongly associated with long-term survival in GBM patients.</description>
        <link>http://www.herpesviridae.org/content/3/1/3</link>
                <dc:creator>Afsar Rahbar</dc:creator>
                <dc:creator>Giuseppe Stragliotto</dc:creator>
                <dc:creator>Abiel Orrego</dc:creator>
                <dc:creator>Inti Peredo</dc:creator>
                <dc:creator>Chato Taher</dc:creator>
                <dc:creator>Jan Willems</dc:creator>
                <dc:creator>Cecilia Soderberg-Naucler1</dc:creator>
                <dc:source>Herpesviridae 2012, null:3</dc:source>
        <dc:date>2012-03-16T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/2042-4280-3-3</dc:identifier>
                                <prism:require>/content/figures/2042-4280-3-3-toc.gif</prism:require>
                <prism:publicationName>Herpesviridae</prism:publicationName>
        <prism:issn>2042-4280</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>3</prism:startingPage>
        <prism:publicationDate>2012-03-16T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.herpesviridae.org/content/3/1/2">
        <title>Evaluation of the IMMULITE (R) 2000 CMV IgM assay</title>
        <description>Background:
Diagnosis of cytomegalovirus (CMV) infection is challenging because of the high rate of asymptomatic infection and the low specificity of associated symptoms and signs. As a result, laboratory testing is an essential aid in making an accurate diagnosis. The presence of CMV IgM is indicative of primary CMV infection. In pregnancy, diagnosis of primary infection is important because primary maternal infection increases fetal infection risk substantially. Fetal infection can result in serious sequelae ranging from neurological deficits to death. Diagnosis among the immunocompromised is also critical for the timely initiation of therapy that can reduce morbidity and mortality risk.
Methods:
The IMMULITE&#174; 2000 CMV IgM assay qualitatively detects CMV IgM antibodies in human serum or plasma to aid in the diagnosis of current or recent CMV infection. To determine expected values in apparently healthy subjects, 136 samples were tested. Reproducibility, normal range, and method comparison studies were also performed to evaluate the assay&apos;s performance. The assay&apos;s reproducibility was evaluated across three sites. Seven hundred and eighteen (n = 718) individual patient serum samples, which included samples from CMV IgM-positive (n = 109, determined by the Abbott IMx CMV or the Diamedix CMV IgM assays), pregnant (n = 210), HIV-positive (n = 30), immunosuppressed (n = 102), and transplant patients (n = 17) and from patients with potentially cross-reacting conditions (n = 136) were evaluated in the method comparison study. The positive, negative, and overall agreement between the IMMULITE 2000 CMV IgM assay and the VIDAS CMV IgM assay (predicate assay) were determined.
Results:
The assay demonstrated excellent reproducibility with a total CV of less than 10%. The positive, negative, and overall agreement between the IMMULITE 2000 assay and the VIDAS assay were &gt; 95% for the method comparison samples. Among potentially cross-reactive samples, the overall agreement between the two assays was 96%. Similarly, among the immunocompromised and pregnant subjects, the overall agreement was ~96% and ~97%, respectively.
Conclusions:
The IMMULITE 2000 CMV IgM assay demonstrated excellent reproducibility, minimal cross-reactivity, and performance comparable to that of the VIDAS CMV IgM assay. It can aid in the diagnosis of acute CMV or recent CMV infection by qualitatively detecting the CMV IgM antibodies in human serum or plasma.</description>
        <link>http://www.herpesviridae.org/content/3/1/2</link>
                <dc:creator>Tricia Bal</dc:creator>
                <dc:creator>Glenn Armstrong</dc:creator>
                <dc:creator>Xiang Han</dc:creator>
                <dc:source>Herpesviridae 2012, null:2</dc:source>
        <dc:date>2012-02-29T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/2042-4280-3-2</dc:identifier>
                                <prism:require>/content/figures/2042-4280-3-2-toc.gif</prism:require>
                <prism:publicationName>Herpesviridae</prism:publicationName>
        <prism:issn>2042-4280</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>2</prism:startingPage>
        <prism:publicationDate>2012-02-29T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.herpesviridae.org/content/3/1/1">
        <title>Characterization of Epstein-Barr virus (EBV)-infected cells in EBV-associated hemophagocytic lymphohistiocytosis in two patients with X-linked lymphoproliferative syndrome type 1 and type 2</title>
        <description>Background:
X-linked lymphoproliferative syndrome (XLP) is a rare inherited immunodeficiency by an extreme vulnerability to Epstein-Barr virus (EBV) infection, frequently resulting in hemophagocytic lymphohistiocytosis (HLH). XLP are now divided into type 1 (XLP-1) and type 2 (XLP-2), which are caused by mutations of SH2D1A/SLAM-associated protein (SAP) and X-linked inhibitor of apoptosis protein (XIAP) genes, respectively. The diagnosis of XLP in individuals with EBV-associated HLH (EBV-HLH) is generally difficult because they show basically similar symptoms to sporadic EBV-HLH. Although EBV-infected cells in sporadic EBV-HLH are known to be mainly in CD8+ T cells, the cell-type of EBV-infected cells in EBV-HLH seen in XLP patients remains undetermined.
Methods:
EBV-infected cells in two patients (XLP-1 and XLP-2) presenting EBV-HLH were evaluated by in EBER-1 in situ hybridization or quantitative PCR methods.
Results:
Both XLP patients showed that the dominant population of EBV-infected cells was CD19+ B cells, whereas EBV-infected CD8+ T cells were very few.
Conclusions:
In XLP-related EBV-HLH, EBV-infected cells appear to be predominantly B cells. B cell directed therapy such as rituximab may be a valuable option in the treatment of EBV-HLH in XLP patients.</description>
        <link>http://www.herpesviridae.org/content/3/1/1</link>
                <dc:creator>Xi Yang</dc:creator>
                <dc:creator>Taizo Wada</dc:creator>
                <dc:creator>Ken-ichi Imadome</dc:creator>
                <dc:creator>Naonori Nishida</dc:creator>
                <dc:creator>Takeo Mukai</dc:creator>
                <dc:creator>Mitsuhiro Fujiwara</dc:creator>
                <dc:creator>Haruka Kawashima</dc:creator>
                <dc:creator>Fumiyo Kato</dc:creator>
                <dc:creator>Shigeyoshi Fujiwara</dc:creator>
                <dc:creator>Akihiro Yachie</dc:creator>
                <dc:creator>Xiaodong Zhao</dc:creator>
                <dc:creator>Toshio Miyawaki</dc:creator>
                <dc:creator>Hirokazu Kanegane</dc:creator>
                <dc:source>Herpesviridae 2012, null:1</dc:source>
        <dc:date>2012-02-10T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/2042-4280-3-1</dc:identifier>
                                <prism:require>/content/figures/2042-4280-3-1-toc.gif</prism:require>
                <prism:publicationName>Herpesviridae</prism:publicationName>
        <prism:issn>2042-4280</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>1</prism:startingPage>
        <prism:publicationDate>2012-02-10T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.herpesviridae.org/content/2/1/10">
        <title>Evolving evidence implicates cytomegalovirus as a promoter of malignant glioma pathogenesis </title>
        <description>Human cytomegalovirus (HCMV) was first reported to be strongly associated with human malignant gliomas in 2002. HCMV is a herpesvirus that causes congenital brain infection and multi-organ disease in immumocompromised individuals. Malignant gliomas are the most common and aggressive adult brain tumors and glioblastoma multiforme (GBM), the highest grade glioma, is associated with a life expectancy of less than two years. HCMV gene products encode for multiple proteins that can promote the various signaling pathways critical to tumor growth, including those involved in mitogenesis, mutagenesis, apoptosis, inflammation, angiogenesis, invasion and immuno-evasion. Several groups have now demonstrated that human malignant gliomas are universally infected with HCMV and express gene products that can promote key signaling pathways in glioma pathogenesis. In this review I discuss specific HCMV gene products that we and others have recently found to be expressed in GBM in vivo, including the HCMV IE1, US28, gB and IL-10 proteins. The roles these HCMV gene products play in dysregulating key pathways in glioma biology, including the PDGFR, AKT, STAT3, and monocyte/microglia function are discussed. Finally, I review emerging human clinical trials for GBM based on anti-HCMV strategies.</description>
        <link>http://www.herpesviridae.org/content/2/1/10</link>
                <dc:creator>Charles Cobbs</dc:creator>
                <dc:source>Herpesviridae 2011, null:10</dc:source>
        <dc:date>2011-10-26T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/2042-4280-2-10</dc:identifier>
                                <prism:require>/content/figures/2042-4280-2-10-toc.gif</prism:require>
                <prism:publicationName>Herpesviridae</prism:publicationName>
        <prism:issn>2042-4280</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>10</prism:startingPage>
        <prism:publicationDate>2011-10-26T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.herpesviridae.org/content/2/1/9">
        <title>The effect of murine cytomegalovirus IE-3 specific shRNA is dependent on intragenic target site due to multiple transcription initiation sites</title>
        <description>Background:
Murine cytomegalovirus (MCMV) is closely related to human cytomegalovirus (HCMV) which is responsible for a variety of diseases, including retinitis, in immunocompromised individuals. Small inhibitory RNA molecules directed against essential viral regulatory genes may prove clinically useful.
Methods:
Small hairpin RNAs (shRNAs) directed against the essential MCMV immediate early-3 gene (IE-3) were designed and tested in vitro at m.o.i.&apos;s of 2 and 0.2 to determine if virus replication could be inhibited.
Results:
At m.o.i. = 2, a MCMV IE-3 specific shRNA specific for sequences at the beginning of exon 5 inhibited virus replication with a maximum decrease in virus titer of approximately two logs at day 5 p.i. Surprisingly, however, at m.o.i. = 0.2, the same shRNA enhanced virus replication. In the latter case, the main IE-3 product observed in infected cells was not the expected 88 kd full length IE-3 protein observed at high m.o.i. but rather a truncated 45 kd form of this protein. Rapid analysis of 5&apos; cDNA ends (5&apos; RACE) indicated that substantial differences exist in the transcript profile produced by the IE-3 gene at low and high m.o.i. early after infection and that multiple transcripts are produced under both conditions. One such transcript, which originated in exon 5 of the IE-3 gene, was located outside the region targeted by our shRNA and was the major transcript produced at low m.o.i. Targeting of this exon 5 transcript with a second shRNA resulted in inhibition of virus replication at both low and high m.o.i.
Conclusions:
These studies indicate that IE-3 has a complex transcriptional profile and that shRNA targeting of this and other viral regulatory genes which produce multiple transcripts may have unexpected effects on virus replication.</description>
        <link>http://www.herpesviridae.org/content/2/1/9</link>
                <dc:creator>Brendan Marshall</dc:creator>
                <dc:creator>Ming Zhang</dc:creator>
                <dc:creator>Sally Atherton</dc:creator>
                <dc:source>Herpesviridae 2011, null:9</dc:source>
        <dc:date>2011-09-18T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/2042-4280-2-9</dc:identifier>
                                <prism:require>/content/figures/2042-4280-2-9-toc.gif</prism:require>
                <prism:publicationName>Herpesviridae</prism:publicationName>
        <prism:issn>2042-4280</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>9</prism:startingPage>
        <prism:publicationDate>2011-09-18T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.herpesviridae.org/content/2/1/8">
        <title>Deciphering the role of Epstein-Barr virus in the pathogenesis of T and NK cell lymphoproliferations </title>
        <description>Epstein-Barr virus (EBV) is a highly successful herpesvirus, colonizing more than 90% of the adult human population worldwide, although it is also associated with various malignant diseases. Primary infection is usually clinically silent, and subsequent establishment of latency in the memory B lymphocyte compartment allows persistence of the virus in the infected host for life. EBV is so markedly B-lymphotropic when exposed to human lymphocytes in vitro that the association of EBV with rare but distinct types of T and NK cell lymphoproliferations was quite unexpected. Whilst relatively rare, these EBV-associated T and NK lymphoproliferations can be therapeutically challenging and prognosis for the majority of patients is dismal. In this review, we summarize the current knowledge on the role of EBV in the pathogenesis of these tumours, and the implications for treatment.</description>
        <link>http://www.herpesviridae.org/content/2/1/8</link>
                <dc:creator>Christopher Fox</dc:creator>
                <dc:creator>Claire Shannon-Lowe</dc:creator>
                <dc:creator>Martin Rowe</dc:creator>
                <dc:source>Herpesviridae 2011, null:8</dc:source>
        <dc:date>2011-09-07T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/2042-4280-2-8</dc:identifier>
                                <prism:require>/content/figures/2042-4280-2-8-toc.gif</prism:require>
                <prism:publicationName>Herpesviridae</prism:publicationName>
        <prism:issn>2042-4280</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>8</prism:startingPage>
        <prism:publicationDate>2011-09-07T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>
